Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMP-GEL 02
- Development stage
- Unknown
- Lead developer
- Oxford Medical Products
- Modality
- Peptides, Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
**OMP-GEL 02** is an Oxford Medical Products preclinical peptide combination product using the company's OMP GEL hydrogel drug-delivery technology. The program is listed as actively available for partnering. Publicly available pipeline information does not disclose the constituent peptide active ingredients, biological targets, intended disease indication, administration route, or a target-specific mechanism of action. Oxford Medical Products describes its OMP GEL technology as a gastroretentive hydrogel platform intended to retain a drug product in the stomach and enable controlled elution to the proximal gastrointestinal tract.
Beyond the preview
Go deeper on OMP-GEL 02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMP-GEL 02.